Cargando…
Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tum...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864587/ https://www.ncbi.nlm.nih.gov/pubmed/36678741 http://dx.doi.org/10.3390/pharmaceutics15010112 |
_version_ | 1784875620006625280 |
---|---|
author | Ali, Rafia Shao, Huimin Varamini, Pegah |
author_facet | Ali, Rafia Shao, Huimin Varamini, Pegah |
author_sort | Ali, Rafia |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations. |
format | Online Article Text |
id | pubmed-9864587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98645872023-01-22 Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations Ali, Rafia Shao, Huimin Varamini, Pegah Pharmaceutics Review Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations. MDPI 2022-12-29 /pmc/articles/PMC9864587/ /pubmed/36678741 http://dx.doi.org/10.3390/pharmaceutics15010112 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ali, Rafia Shao, Huimin Varamini, Pegah Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title_full | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title_fullStr | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title_full_unstemmed | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title_short | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
title_sort | potential nanotechnology-based therapeutics to prevent cancer progression through tme cell-driven populations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864587/ https://www.ncbi.nlm.nih.gov/pubmed/36678741 http://dx.doi.org/10.3390/pharmaceutics15010112 |
work_keys_str_mv | AT alirafia potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations AT shaohuimin potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations AT varaminipegah potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations |